We exploited the emerging potential of gene therapy strategies to design a powerful therapeutic system that combines two key components—AAV vector and -gingerol. In this study, we created an AAV2 construct expressing the proapoptotic protein BIM, which uses HSPG as its primary receptor, to target HSPG-overexpressing melanoma cells. This combination treatment showed promising results in vitro, inducing apoptosis in human melanoma cells. This new platform technology will make a significant contribution to numerous therapeutic applications, most notably for melanoma, including overcoming resistance to conventional anticancer therapies.
Bibliographical notePublisher Copyright:
© 2017 Elsevier B.V.
All Science Journal Classification (ASJC) codes
- Molecular Biology